Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns

被引:167
作者
Ferreira-Gonzalez, Ignacio
Permanyer-Miralda, Gaieta [1 ]
Busse, Jason W.
Bryant, Dianne M.
Montori, Victor M.
Alonso-Coello, Pablo
Walter, Stephen D.
Guyatt, Gordon H.
机构
[1] Hosp Univ Vall Hebron, Serv Cardiol, Unitat Epidemiol, Barcelona 08035, Spain
[2] Autonomous Univ Barcelona, Dept Internal Med, E-08193 Barcelona, Spain
[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada
[4] Univ Western Ontario, Fac Hlth Sci, London, ON N6A 3K7, Canada
[5] Mayo Clin & Mayo Fdn, Coll Med, Div Endocrinol Diabet Metab Nutr & Internal Med, Rochester, MN 55905 USA
[6] Hosp Santa Creu & Sant Pau, Dept Clin Epidemiol & Publ Hlth, Iberoamer Cochrane Ctr, Barcelona, Spain
关键词
composite endpoints; combined outcomes; clinical trials; outcomes; endpoints; overview;
D O I
10.1016/j.jclinepi.2006.10.020
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To investigate the rationale, potential problems and solutions of using composite endpoints (CEPs) for the assessment of intervention effects. Study Design and Setting: This study is a systematic review. We searched MEDLINE, EMBASE, and the Science Citation Index, for publications appearing between 1980 and September 2005, and reviewed potentially informative textbooks. Eligible articles provided a commentary, analysis, or discussion of CEPs for any of the following areas: (1) rationale, (2) interpretation or meaning, (3) advantages, (4) limitations or conceptual problems, and (5) recommendations for use. Results: Seventeen articles and one textbook proved eligible. Decreases in sample size requirements and ability to assess the net effect of an intervention were the most commonly cited advantages. Authors noted the risk of misinterpretation when heterogeneity among components with respect to either patient importance or magnitude of treatment effects as the most salient disadvantage. There were discrepancies between authors concerning the usefulness of CEPs to avoid bias from competing risks and when the direction of the effect of therapy differs across components. Conclusion: Methodologists have given limited attention to CEPs and their views are sometimes contradictory. Further work is needed to establish the role of CEPs in research and in guiding clinical practice. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:651 / 657
页数:7
相关论文
共 25 条
  • [1] [Anonymous], 2003, MULTIPLE ANAL CLIN T
  • [2] AN APPROACH TO EVALUATING THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION THE UNSATISFACTORY OUTCOME END-POINT
    BRAUNWALD, E
    CANNON, CP
    MCCABE, CH
    [J]. CIRCULATION, 1992, 86 (02) : 683 - 687
  • [3] Clinical perspectives on the use of composite endpoints
    Cannon, CP
    [J]. CONTROLLED CLINICAL TRIALS, 1997, 18 (06): : 517 - 529
  • [4] Carneiro Antonio Vaz, 2003, Rev Port Cardiol, V22, P1253
  • [5] Some issues with composite endpoints in clinical trials
    Chi, GYH
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (06) : 609 - 619
  • [6] Lessons learned from recent cardiovascular clinical trials: Part I
    DeMets, DL
    Califf, RM
    [J]. CIRCULATION, 2002, 106 (06) : 746 - 751
  • [7] Composite outcomes in randomized trials - Greater precision but with greater uncertainty?
    Freemantle, N
    Calvert, M
    Wood, J
    Eastaugh, J
    Griffin, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19): : 2554 - 2559
  • [8] Gensini G F, 2004, Minerva Med, V95, P71
  • [9] GENT M, 1996, CONTROL CLIN TRIALS, V18, P546
  • [10] A METHOD OF ASSIGNING SCORES TO THE COMPONENTS OF A COMPOSITE OUTCOME - AN EXAMPLE FROM THE MITI TRIAL
    HALLSTROM, AP
    LITWIN, PE
    WEAVER, WD
    [J]. CONTROLLED CLINICAL TRIALS, 1992, 13 (02): : 148 - 155